Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
From Data Disseminator to Trusted Advisor
Summary
In this episode, Chad Fellers shares insights from his experience as an MSL, highlighting his team's success strategies during COVID-19. He discusses the evolving role of MSLs as trusted advisors and offers advice on how to measure and enhance MSL value. Chad explores the future of Key Opinion Leader (KOL) engagement and the influence of digital platforms, as well as adjustments in travel and administrative duties. He emphasizes the importance of active listening and provides tips for MSLs to build strong advisor relationships. The episode also touches on Chad's personal interests, including streaming favorites and dietary changes influenced by documentaries.
Learn about how MSLs go from data disseminators to trusted advisors in my conversation with Chad Fellers, Director of Medical Science Liasons at Harmony Biosciences.
In this episode we discuss:
-
The success of his team despite COVID.
-
The unique approach their team uses in engaging their KOLs.
-
Measuring and assessing value from an MSL perspective.
-
His stance in leading his MSL team.
-
The future of KOL engagement for MSLs.
-
Effect of the change of less travel to MSLs.
-
How it’s going to look like as things open up.
-
Advice for MSLs to stay focused, on track, and continue to be a trusted advisor.
Medical Science Liaisons, MSL team strategies, Key Opinion Leader engagement, MSL value measurement, trusted advisor role
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary